1. Home
  2. GECC vs NSPR Comparison

GECC vs NSPR Comparison

Compare GECC & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GECC

Great Elm Capital Corp.

HOLD

Current Price

$6.14

Market Cap

79.9M

Sector

Finance

ML Signal

HOLD

Logo InspireMD Inc.

NSPR

InspireMD Inc.

HOLD

Current Price

$0.94

Market Cap

72.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GECC
NSPR
Founded
2016
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
79.9M
72.1M
IPO Year
N/A
2009

Fundamental Metrics

Financial Performance
Metric
GECC
NSPR
Price
$6.14
$0.94
Analyst Decision
Buy
Buy
Analyst Count
2
1
Target Price
$10.75
$4.00
AVG Volume (30 Days)
91.0K
267.5K
Earning Date
05-12-2026
05-04-2026
Dividend Yield
22.06%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,310,000.00
Revenue This Year
$0.92
$57.98
Revenue Next Year
N/A
$95.41
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.63
$0.86
52 Week High
$11.45
$2.93

Technical Indicators

Market Signals
Indicator
GECC
NSPR
Relative Strength Index (RSI) 60.87 33.07
Support Level $5.40 N/A
Resistance Level $7.16 $1.29
Average True Range (ATR) 0.27 0.08
MACD 0.02 -0.01
Stochastic Oscillator 82.78 18.98

Price Performance

Historical Comparison
GECC
NSPR

About GECC Great Elm Capital Corp.

Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. It generates both income and capital appreciation through debt and income-generating equity investments, including investments in finance businesses. The Company operates as a single reportable segment with an investment objective to generate both current income and capital appreciation through debt and equity investments and manages the business on a consolidated basis.

About NSPR InspireMD Inc.

InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.

Share on Social Networks: